Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544
This study is recruiting at 15 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non Small Cell Lung Cancer
- Glioma Glioblastoma Multiforme
- Glioma, Malignant
- Solid Tumor
- Non-Small Cell Adenocarcinoma
- Lung Cancer
- Brain Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Tango Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- April 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic Scottsdale · Scottsdale, AZ
California · 3
- University of California, Irvine · Irvine, CA
- University of California Los Angeles · Los Angeles, CA
- University of California at San Francisco · San Francisco, CA
District of Columbia · 1
- Sibley Memorial Hospital · Washington D.C., DC
Florida · 1
- Mayo Clinic Jacksonville · Jacksonville, FL
Illinois · 1
- Northwestern Memorial Hospital · Chicago, IL
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Minnesota · 1
- Mayo Clinic Cancer Center · Rochester, MN
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- NYU Langone Health · New York, NY
Ohio · 1
- Ohio State University Comprehensive Cancer Center · Columbus, OH
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Utah · 1
- University of Utah, Huntsman Cancer Institute · Salt Lake City, UT
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.